The georgetown purchase was so huge. There's a not

The georgetown purchase was so huge. There's a notable probability that lympro, even with improved multivariate data, isn't good enough, meaning not enough for clinicals to change course now instead of waiting to see if a really certain test comes out. Our potential 3 prong approach with Gtown +Lympro is evidence of better things to come anyway. It may still be superior to PET, and of course other unproven methods for now, but I think by 2016 we could have a 99% certain test between lympro/lipid/exosome that not only helps advance trials by providing accuracy, but tells researchers an incredible amount about the disease and how drug candidates might interact. Recall, its not just headway we have to make on the test, but headway we have to make on the science for early/and pre ALZ patients for the real drug that will win in the end. The knowledge we provide the scientific community will be our power in the financial outcomes we all want. Cool, shed some skin for tau, look in the eye, all that does is possibly reveal who has the disease, but it won't help the science, merely the scientific process (and those are still maybes). For these big gov/private studies like the 10,000 patient A4 study, I think we've got the cumulative answer now. And i would love for Lympro to be adopted as is anyway. The momentum behind our approach should and is attracting investment. Lympro affectiveness combines with good initial data we confirm with G town will get people signing up in advance. We must be patient. Chaka knows what's up, he's got a birds eye view on the field, as do Stern, Cummings, and Trezpacz.